Mesoblast has entered into an Agreement with Celgene.
Celgene will purchase Mesoblast stock and has a six-month right of first refusal to certain disease fields.
Celgene will purchase 15.3 million ordinary shares in Mesoblast Limited for a consideration of A$58.5 million/US$45 million at a price of A$3.82 per share.
|Searching for more deal information? Current Partnering offers the following options:
In addition, Celgene has a six-month right of first refusal with respect to Mesoblast's proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies